Trial Number

112-20

Condition

Cystic Fibrosis

Participant Age Range

All ages

Participant Gender

Any

Enrolling Participants

Yes

Overview

The effect of CFTR Modulator Trikafta (Elexacaftor/ivacaftor/tezacaftor) on lower airway microbiome in Cystic Fibrosis patients

Efficacious CFTR modulation may contribute to lower frequency of culture positivity for Pseudomonas aeruginosa and other respiratory pathogens, particularly in Cystic Fibrosis patients with less established disease. Studies have shown that patients receiving lumacaftor/ivacaftor for CF had significantly delayed acquisition of P. aeruginosa and Staphylococcus aureus. These studies suggest that the existing CFTR modulators, particularly ivacaftor, favorably impact CF microbiology, but the durability of these effects is currently uncertain.

Provider

Related Clinical Trials

Click on the category you are interested in.

Name
Address
Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
Are you a current MemorialCare patient?
This registration is for:
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.